Hot Longevity Mandate: US-Based Drug Development Company

10 Aug

The drug development company was founded in 2016 and is headquartered in the US. In 2016, they closed a $49 M fund to in-license 4-6 IND-ready assets and develop them through Phase 2b. After proof-of-concept is established, they will seek to exit. Roughly 90% of the fund will be used to fund development, with clinical trials carried out by the firm. They are particularly interested in therapeutics falling in the sectors of neuroscience and immunology.

The firm is seeking small molecules and biologics in the areas of neuroscience and immunology that can improve patient lives. They do not consider drugs for highly crowded spaces, for example oncology or disease-modifying drugs for Alzheimer’s. Levadopa-induced dyskinesia in Parkinson’s and ataxia have been areas of interest, and they will consider therapeutics for orphan and rare diseases. Drug platforms addressing self-similar indications/targets are also of interest.

The firm looks for IND-ready drugs that can be developed or re-purposed, and will conduct a thorough due diligence taking 6 months to a year. The opportunity should have a clear regulatory and development pathway and good prospects for an exit within 4 years of acquisition. With strong scientific backgrounds themselves, the firm respects the expertise of the innovators. They will work with founders to arrange a deal, and are open to negotiating option agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: